Tenofovir versus placebo to prevent perinatal transmission of hepatitis B

• Main Authors: G. Jourdain, N. Ngo-Giang-Huong, L. Harrison, L. Decker, W. Khamduang, C. Tierney, N. Salvadori, T. R. Cressey, W. Sirirungsi, J. Achalapong, P. Yuthavisuthi, P. Kanjanavikai, O. P. Na Ayudhaya, T. Siriwachirachai, S. Prommas, P. Sabsanong, A. Limtrakul, S. Varadisai, C. Putiyanun, P. Suriyachai, P. Liampongsabuddhi, S. Sangsawang, W. Matanasarawut, S. Buranabanjasatean, P. Puernngooluerm, C. Bowonwatanuwong, T. Puthanakit, V. Klinbuayaem, S. Thongsawat, S. Thanprasertsuk, G. K. Siberry, D. H. Watts, N. Chakhtoura, T. V. Murphy, N. P. Nelson, R. T. Chung, S. Pol, N. Chotivanich
• 格式: 雜誌
• 出版: 2018
• 主題: Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85043605260&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/58962

Copyright © 2018 Massachusetts Medical Society. BACKGROUND Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin. METHODS In this multicenter, double-blind clinical...